Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 995 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Comparison control condition Clear all

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BEA 2180 BR, Tiotropium Bromide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 100 Years
Enrollment: 2,080 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 56
States / cities: Jasper, Alabama • Mobile, Alabama • Berkeley, California + 50 more

Conditions: Drinking, Alcohol, Drinking Behavior
Interventions: Control App Version, Standard App Version, Experimental, Feedback App Version; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 25 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
Interventions: Drug Eluting Balloon, Drug eluting stent, Plain old balloon angioplasty; Device · Procedure
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 48
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • La Jolla, California + 40 more

Conditions: Lynch Syndrome
Interventions: Electronic Consent (iPad); Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 703 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Major Depressive Disorder (MDD)
Interventions: H7-Coil, H1-Coil; Device
Lead sponsor: Brainsway; Industry
Eligibility: 22 Years to 68 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: La Jolla, California • Los Angeles, California • Juno Beach, Florida + 4 more

Conditions: Depression, Anxiety
Interventions: ADAPT Platform (Treatment), ADAPT Comparison (Control); Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Irvine, California

Conditions: Generalized Anxiety Disorder
Interventions: Not listed
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Healthy Volunteers
Interventions: Rhodiola rosea (low dose), Rhodiola rosea (high dose), Placebo capsules; Dietary Supplement
Lead sponsor: Jacksonville State University; Other
Eligibility: 18 Weeks to 40 Weeks
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Jacksonville, Alabama

Conditions: Primary Care Patients, Primary Care Center
Interventions: Providing reminder and resources via messages, Reminder and resources sent via navigation, Regular care; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Aurora, Colorado • Denver, Colorado • Lone Tree, Colorado + 1 more

Conditions: Melanoma, Neoplasm Metastasis
Interventions: CC 5013; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • San Francisco, California + 18 more

Conditions: Spinocerebellar Ataxias
Interventions: BHV-4157; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bulimia Nervosa
Interventions: FBT-BN, SPT; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 12 Years to 19 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sleep
Interventions: LED portable light therapy bulb; Other
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Health Care Transition Readiness, Health Literacy, Self Efficacy, Emotional Wellbeing, Appointment Attendance
Interventions: Health Education Videos, GotTransition.org Website; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 12 Years to 17 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stroke, Acute
Interventions: Analyze plasma free fatty acid in blood; Diagnostic Test
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Cervical Cancer
Interventions: Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 38
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 35 more

Conditions: Social Anxiety Disorder
Interventions: Group CBT for Social Anxiety Disorder, Sertraline, Individual CBT for Social Anxiety Disorder; Behavioral · Drug
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 50 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depressive Disorder
Interventions: Extended-release Bupropion Hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 48
States / cities: Anchorage, Alaska • Hamden, Connecticut • Newark, Delaware + 41 more

Conditions: Sleep Initiation and Maintenance Disorders, Pregnancy
Interventions: No Intervention; Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: 16 Years to 49 Years · Female only
Enrollment: 861 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Nutley, New Jersey

Conditions: Kidney Disease
Interventions: Behavioral Interventions for Dialysis Facilities; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
Interventions: Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone; Drug
Lead sponsor: Yih-Ing Hser; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: El Dorado, Arkansas • Garberville, California • Gibson City, Illinois + 4 more

Conditions: Problem Behavior, Intellectual Disability, Developmental Disorder
Interventions: Functional communication training; Behavioral
Lead sponsor: Western Kentucky University; Other
Eligibility: 3 Years to 11 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Bowling Green, Kentucky

Conditions: COVID-19
Interventions: NDV-HXP-S-KP.2, COVID-19 mRNA Vaccine; Biological
Lead sponsor: CastleVax Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Colorado Springs, Colorado • Burlington, Massachusetts

Conditions: Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Sexually Transmitted Diseases, Viral, Sexually Transmitted Diseases, Warts
Interventions: VP-102 and applicator, Placebo; Combination Product
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Plainfield, Indiana • Baton Rouge, Louisiana • Clarkston, Michigan + 1 more

Search by objective public record fields.

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

Inhibitory Control Smartphone App

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants

Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)

Evaluation of a Crowd-Powered Web Platform for Depression and Anxiety

Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)

Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults

Testing the Impact of the MOHR Follow-up Support

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

Family Therapy for Adolescent Bulimia Nervosa

Effects of Combined Blue and Red Home-Based Light Therapy on Sleep in Adults With Self-Reported Sleep Difficulties

Health Care Transition Readiness Short-Form Video Intervention

Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety

Seasonal Affective Depression (SAD) Study

A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population

The Reducing Disparities in Access to kidNey Transplantation (RaDIANT) Community Study

Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)

Improving Treatment for Children With Intellectual and Developmental Disabilities and Problem Behavior in Schools

Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts